Literature DB >> 21038783

Performance status and deaths among children registered in Kuwait National Primary ImmunoDeficiency Disorders Registry.

Waleed Al-Herz1, Mohammad E Zainal, Hamid M Alenezi, Khalid Husain, Salem H Alshemmari.   

Abstract

Children with primary immunodeficiency disorders (PIDD) have an increased risk of suffering from physical, social, and psychological problems. The aim of this study was to evaluate the performance status and mortality of children with PIDD in Kuwait and to determine the variables and co-morbidities that may affect their performance and risk of death. The data for the children were obtained from Kuwait National Primary Immunodeficiency Disorders Registry describes the patients' characteristics, comorbidities and their treatment regimens. Each patient was scored using the Lansky Play Performance Scale (LPPS), and we evaluated the number of deaths among the children and the effects of different variables on their LPPS scores and mortality. We examined 98 pediatric patients with a mean delay in diagnosis of 21.2 months. Antimicrobial prophylaxis was administered to 57.2% of the patients, whereas intravenous immunoglobulin (IVIG) therapy was used in 44%. Eight patients underwent bone marrow transplants. The mean LPPS score for all the patients was 65.5, and there was a significant disparity in the mean LPPS scores across PIDD categories. Twenty-one patients died. The variables that were found to have a significant effect on both the LPPS score and the risk of death were an age of onset of less than 6 months, a history of CMV infection, parental consanguinity, the use of antimicrobial prophylaxis and IVIG therapy. In conclusion, patients with PIDD have a poor performance status and a high rate of mortality. Early diagnosis and aggressive therapeutic interventions directed at patients with early onset of symptoms and CMV infections can help improve the quality of life of patients with PIDD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21038783

Source DB:  PubMed          Journal:  Asian Pac J Allergy Immunol        ISSN: 0125-877X            Impact factor:   2.310


  6 in total

1.  Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry.

Authors:  Asghar Aghamohammadi; Payam Mohammadinejad; Hassan Abolhassani; Babak Mirminachi; Masoud Movahedi; Mohammad Gharagozlou; Nima Parvaneh; Vaheid Zeiaee; Bahram Mirsaeed-Ghazi; Zahra Chavoushzadeh; Alireza Mahdaviani; Mahboubeh Mansouri; Sedigheh Yousefzadegan; Bahareh Sharifi; Fariborz Zandieh; Ehsan Hedayat; Ali Nadjafi; Roya Sherkat; Behzad Shakerian; Mahnaz Sadeghi-Shabestari; Reza Farid Hosseini; Farahzad Jabbari-Azad; Hamid Ahanchian; Fatemeh Behmanesh; Mohammadreza Zandkarimi; Afshin Shirkani; Taher Cheraghi; Abbas Fayezi; Iraj Mohammadzadeh; Reza Amin; Soheila Aleyasin; Mojgan Moghtaderi; Javad Ghaffari; Saba Arshi; Naser Javahertrash; Mohammad Nabavi; Mohammad Hassan Bemanian; Alireza Shafiei; Najmedin Kalantari; Akefeh Ahmadiafshar; Hossein Ali Khazaei; Lida Atarod; Nima Rezaei
Journal:  J Clin Immunol       Date:  2014-05       Impact factor: 8.317

2.  Primary Immunodeficiency Diseases in Oman: 10-Year Experience in a Tertiary Care Hospital.

Authors:  Salem Al-Tamemi; Shafiq Ur Rehman Naseem; Nabila Al-Siyabi; Ibtisam El-Nour; Abdulhakim Al-Rawas; David Dennison
Journal:  J Clin Immunol       Date:  2016-10-03       Impact factor: 8.317

3.  Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders.

Authors:  Asbjørg Stray-Pedersen; Hanne Sørmo Sorte; Pubudu Samarakoon; Tomasz Gambin; Ivan K Chinn; Zeynep H Coban Akdemir; Hans Christian Erichsen; Lisa R Forbes; Shen Gu; Bo Yuan; Shalini N Jhangiani; Donna M Muzny; Olaug Kristin Rødningen; Ying Sheng; Sarah K Nicholas; Lenora M Noroski; Filiz O Seeborg; Carla M Davis; Debra L Canter; Emily M Mace; Timothy J Vece; Carl E Allen; Harshal A Abhyankar; Philip M Boone; Christine R Beck; Wojciech Wiszniewski; Børre Fevang; Pål Aukrust; Geir E Tjønnfjord; Tobias Gedde-Dahl; Henrik Hjorth-Hansen; Ingunn Dybedal; Ingvild Nordøy; Silje F Jørgensen; Tore G Abrahamsen; Torstein Øverland; Anne Grete Bechensteen; Vegard Skogen; Liv T N Osnes; Mari Ann Kulseth; Trine E Prescott; Cecilie F Rustad; Ketil R Heimdal; John W Belmont; Nicholas L Rider; Javier Chinen; Tram N Cao; Eric A Smith; Maria Soledad Caldirola; Liliana Bezrodnik; Saul Oswaldo Lugo Reyes; Francisco J Espinosa Rosales; Nina Denisse Guerrero-Cursaru; Luis Alberto Pedroza; Cecilia M Poli; Jose L Franco; Claudia M Trujillo Vargas; Juan Carlos Aldave Becerra; Nicola Wright; Thomas B Issekutz; Andrew C Issekutz; Jordan Abbott; Jason W Caldwell; Diana K Bayer; Alice Y Chan; Alessandro Aiuti; Caterina Cancrini; Eva Holmberg; Christina West; Magnus Burstedt; Ender Karaca; Gözde Yesil; Hasibe Artac; Yavuz Bayram; Mehmed Musa Atik; Mohammad K Eldomery; Mohammad S Ehlayel; Stephen Jolles; Berit Flatø; Alison A Bertuch; I Celine Hanson; Victor W Zhang; Lee-Jun Wong; Jianhong Hu; Magdalena Walkiewicz; Yaping Yang; Christine M Eng; Eric Boerwinkle; Richard A Gibbs; William T Shearer; Robert Lyle; Jordan S Orange; James R Lupski
Journal:  J Allergy Clin Immunol       Date:  2016-07-16       Impact factor: 10.793

Review 4.  Health-related quality of life in patients with primary immunodeficiency disease.

Authors:  Fonda Jiang; Troy R Torgerson; Andrew G Ayars
Journal:  Allergy Asthma Clin Immunol       Date:  2015-09-29       Impact factor: 3.406

Review 5.  Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell Transplantation.

Authors:  Jan Styczynski
Journal:  Infect Dis Ther       Date:  2017-12-04

6.  Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".

Authors:  B Bienvenu; G Cozon; C Hoarau; M Pasquet; P Cherin; P Clerson; E Hachulla; J C Crave; J C Delain; R Jaussaud
Journal:  Orphanet J Rare Dis       Date:  2016-06-22       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.